SDC1 and plasma cell myeloma: Jiang H. et al. developed modified NK cells expressing a syndecan-1-specific chimeric antigen receptor (CAR), that showed enhanced in vitro and in vivo cytotoxicity against syndecan-1 positive multiple myeloma cells, presenting a new possible approach for efficient and specific cancer immunotherapy (142).